Compare · MENS vs NVO
MENS vs NVO
Side-by-side comparison of Jyong Biotech Ltd. (MENS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MENS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 1104.0x MENS ($166.5M).
- Over the past year, MENS is down 77.4% and NVO is down 34.2% - NVO leads by 43.1 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 2 for MENS).
- NVO has more recent analyst coverage (25 ratings vs 0 for MENS).
- Company
- Jyong Biotech Ltd.
- Novo Nordisk A/S
- Price
- $2.20-4.35%
- $41.18+6.93%
- Market cap
- $166.5M
- $183.82B
- 1M return
- +6.28%
- +13.32%
- 1Y return
- -77.38%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 2
- 5
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MENS
- SEC Form 3 filed by new insider Zhang Wei (Vivi)
- SEC Form 3 filed by new insider Kuo Fu-Feng
- SEC Form 3 filed by new insider Hsu Ming Tsan
- SEC Form 3 filed by new insider Hsu Feng-Lin
- SEC Form 3 filed by new insider Hsu Feng-Lin
- SEC Form 3 filed by new insider Fan Hung-Shu
- SEC Form 3 filed by new insider Chi Pang-Chieh
- Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
- Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia
- SEC Form 6-K filed by Jyong Biotech Ltd.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S